{
  "slug": "ldl-ascvd",
  "title": "LDL Particle Concentration as a Causal Driver of Atherosclerotic Cardiovascular Disease",
  "claim": "In humans, a higher cumulative circulating concentration of LDL-class apoB-containing particles increases atherosclerotic cardiovascular disease risk by increasing the flux and retention of those particles in the arterial intima; interventions that reduce this exposure should reduce atherosclerotic events.",
  "update_date": "2026-10-05",
  "search_cutoff": "2026-10-05",
  "framework_for_addendum": "HSEF v5.3 causal distinctions",
  "historical_scorecard_schema": "5.4",
  "regraded": false,
  "status": "curated_local_addendum",
  "full_academic_review_complete": false,
  "summary": "Human genetics, multiple drug classes and experimental retention evidence support a causal role for atherogenic lipoprotein exposure. Remaining gaps concern the best exposure metric, lifetime treatment timing and populations in which lowering does not reduce the measured outcome.",
  "timeline": [
    {
      "year": "1994",
      "source_id": "P7968073",
      "design": "4S randomized statin trial",
      "finding": "Simvastatin reduced coronary events and improved survival in established coronary disease.",
      "limit": "A drug effect is not an isolated manipulation of particle count versus cholesterol content.",
      "historical_anchor_only": false
    },
    {
      "year": "2002",
      "source_id": "P12066187",
      "design": "Proteoglycan-binding-defective LDL mouse experiment",
      "finding": "Reduced arterial retention affinity lowered atherosclerosis.",
      "limit": "A model mechanism does not quantify every human risk pathway.",
      "historical_anchor_only": false
    },
    {
      "year": "2005",
      "source_id": "P16034009",
      "design": "4D randomized dialysis trial",
      "finding": "Atorvastatin did not significantly improve the composite primary endpoint.",
      "limit": "Advanced renal disease and competing pathology bound broad extrapolation.",
      "historical_anchor_only": false
    },
    {
      "year": "2006",
      "source_id": "P16554528",
      "design": "PCSK9 genetic cohort",
      "finding": "Lifelong genetically lower LDL was associated with fewer coronary events.",
      "limit": "Genetic exposure timing and possible pleiotropy differ from starting treatment later.",
      "historical_anchor_only": false
    },
    {
      "year": "2015",
      "source_id": "P26039521",
      "design": "IMPROVE-IT randomized trial",
      "finding": "Adding ezetimibe lowered LDL further and improved cardiovascular outcomes.",
      "limit": "The achieved exposure changes multiple correlated lipid measures.",
      "historical_anchor_only": false
    },
    {
      "year": "2017",
      "source_id": "P28304224",
      "design": "FOURIER randomized trial",
      "finding": "PCSK9 inhibition lowered LDL and reduced cardiovascular events.",
      "limit": "Background therapy, population risk and follow-up duration define scope.",
      "historical_anchor_only": false
    },
    {
      "year": "2020",
      "source_id": "P32203549",
      "design": "Multivariable Mendelian randomization",
      "finding": "ApoB accounted for much of the modeled lipid–coronary relationship.",
      "limit": "Correlated traits and conditional instrument strength limit exclusive component attribution.",
      "historical_anchor_only": false
    },
    {
      "year": "2023",
      "source_id": "P36876740",
      "design": "CLEAR Outcomes randomized trial",
      "finding": "Bempedoic acid reduced major events in statin-intolerant patients.",
      "limit": "Benefits and adverse effects remain population- and drug-specific.",
      "historical_anchor_only": false
    },
    {
      "year": "2025",
      "source_id": "P41211925",
      "design": "VESALIUS-CV randomized trial",
      "finding": "Evolocumab reduced first events in high-risk people without previous myocardial infarction or stroke.",
      "limit": "Atherosclerosis or diabetes eligibility is not unrestricted low-risk primary prevention.",
      "historical_anchor_only": false
    }
  ],
  "gaps": [
    {
      "id": "G1",
      "question": "When does LDL cholesterol cease to represent the causal exposure adequately?",
      "source_ids": [
        "P32203549",
        "P16554528",
        "P26039521",
        "P28304224"
      ],
      "alternative": "Particle number, particle type and cholesterol content may diverge while conventional LDL-C remains correlated.",
      "discriminating_test": "Prospective discordance analyses and orthogonal instruments with conditional-strength checks; measure apoB, LDL-C, remnants and lipoprotein(a).",
      "gap_type": "bounded_causal_uncertainty",
      "interpretation": "An unresolved inference or scope limit in the checked evidence, not a claim that no relevant study exists anywhere."
    },
    {
      "id": "G2",
      "question": "Why do advanced dialysis populations differ?",
      "source_ids": [
        "P16034009",
        "P7968073",
        "P28304224"
      ],
      "alternative": "Competing nonatherosclerotic events or irreversible disease may dominate outcomes.",
      "discriminating_test": "Mechanism-specific outcome adjudication and disease-stage studies with competing-risk analyses; distinguish null benefit in a population from absence of causal atherogenesis.",
      "gap_type": "bounded_causal_uncertainty",
      "interpretation": "An unresolved inference or scope limit in the checked evidence, not a claim that no relevant study exists anywhere."
    },
    {
      "id": "G3",
      "question": "How much benefit comes from earlier and longer exposure reduction?",
      "source_ids": [
        "P16554528",
        "P41211925",
        "P36876740"
      ],
      "alternative": "Short clinical trials underestimate cumulative lifelong exposure effects and can miss later harms.",
      "discriminating_test": "Extended follow-up and earlier-treatment randomized evidence where feasible, with absolute-risk and adherence measures; do not equate genetic and drug effect sizes.",
      "gap_type": "bounded_causal_uncertainty",
      "interpretation": "An unresolved inference or scope limit in the checked evidence, not a claim that no relevant study exists anywhere."
    },
    {
      "id": "G4",
      "question": "Which residual risks are not mediated by LDL lowering?",
      "source_ids": [
        "P12066187",
        "P32203549",
        "P28304224"
      ],
      "alternative": "Inflammation, other apoB particles, thrombosis and established plaque can contribute independently.",
      "discriminating_test": "Factorial or complementary interventions with prespecified lipid and nonlipid pathways, hard events and target engagement.",
      "gap_type": "bounded_causal_uncertainty",
      "interpretation": "An unresolved inference or scope limit in the checked evidence, not a claim that no relevant study exists anywhere."
    }
  ],
  "source_cards": [
    {
      "id": "P7968073",
      "pmid": "7968073",
      "doi": "",
      "title": "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7968073/",
      "issue_year": "1994",
      "electronic_date": "",
      "access_depth": "abstract_excerpt_checked",
      "checked_details": "Primary record and selected abstract passages checked; no complete-paper appraisal credited.",
      "publication_types": [
        "Clinical Trial",
        "Journal Article",
        "Randomized Controlled Trial",
        "Research Support, Non-U.S. Gov't"
      ],
      "correction_notices": [],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "abstract_metadata",
      "complete_paper_examined_in_this_update": false
    },
    {
      "id": "P12066187",
      "pmid": "12066187",
      "doi": "10.1038/nature00804",
      "title": "Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12066187/",
      "issue_year": "2002",
      "electronic_date": "",
      "access_depth": "abstract_excerpt_checked",
      "checked_details": "Primary record and selected abstract passages checked; no complete-paper appraisal credited.",
      "publication_types": [
        "Journal Article",
        "Research Support, Non-U.S. Gov't",
        "Research Support, U.S. Gov't, P.H.S."
      ],
      "correction_notices": [],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "abstract_metadata",
      "complete_paper_examined_in_this_update": false
    },
    {
      "id": "P16034009",
      "pmid": "16034009",
      "doi": "10.1056/NEJMoa043545",
      "title": "Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16034009/",
      "issue_year": "2005",
      "electronic_date": "",
      "access_depth": "abstract_excerpt_checked",
      "checked_details": "Primary record and selected abstract passages checked; no complete-paper appraisal credited.",
      "publication_types": [
        "Clinical Trial",
        "Journal Article",
        "Multicenter Study",
        "Randomized Controlled Trial",
        "Research Support, Non-U.S. Gov't"
      ],
      "correction_notices": [
        {
          "type": "ErratumIn",
          "pmid": "",
          "note": ""
        }
      ],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "abstract_metadata",
      "complete_paper_examined_in_this_update": false,
      "notice_check_scope": "Linked notice presence was checked in the primary record; its scientific impact was not verified in this update."
    },
    {
      "id": "P16554528",
      "pmid": "16554528",
      "doi": "10.1056/NEJMoa054013",
      "title": "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16554528/",
      "issue_year": "2006",
      "electronic_date": "",
      "access_depth": "abstract_excerpt_checked",
      "checked_details": "Primary record and selected abstract passages checked; no complete-paper appraisal credited.",
      "publication_types": [
        "Comparative Study",
        "Journal Article",
        "Research Support, N.I.H., Extramural",
        "Research Support, Non-U.S. Gov't"
      ],
      "correction_notices": [],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "abstract_metadata",
      "complete_paper_examined_in_this_update": false
    },
    {
      "id": "P26039521",
      "pmid": "26039521",
      "doi": "10.1056/NEJMoa1410489",
      "title": "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26039521/",
      "issue_year": "2015",
      "electronic_date": "2015-06-03",
      "access_depth": "abstract_excerpt_checked",
      "checked_details": "Primary record and selected abstract passages checked; no complete-paper appraisal credited.",
      "publication_types": [
        "Comparative Study",
        "Journal Article",
        "Multicenter Study",
        "Randomized Controlled Trial",
        "Research Support, Non-U.S. Gov't"
      ],
      "correction_notices": [],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "abstract_metadata",
      "complete_paper_examined_in_this_update": false
    },
    {
      "id": "P28304224",
      "pmid": "28304224",
      "doi": "10.1056/NEJMoa1615664",
      "title": "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28304224/",
      "issue_year": "2017",
      "electronic_date": "2017-03-17",
      "access_depth": "abstract_excerpt_checked",
      "checked_details": "Primary record and selected abstract passages checked; no complete-paper appraisal credited.",
      "publication_types": [
        "Journal Article",
        "Multicenter Study",
        "Randomized Controlled Trial"
      ],
      "correction_notices": [],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "abstract_metadata",
      "complete_paper_examined_in_this_update": false
    },
    {
      "id": "P32203549",
      "pmid": "32203549",
      "doi": "10.1371/journal.pmed.1003062",
      "title": "Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32203549/",
      "issue_year": "2020",
      "electronic_date": "2020-03-23",
      "access_depth": "full_text_partial",
      "checked_details": "Methods table and instrument-strength paragraph: conditional apoB F-statistics of 36 and 66 are present in the primary text, although unavailable in Consensus excerpts. These do not imply every correlated exposure is independently identified.",
      "publication_types": [
        "Journal Article",
        "Research Support, Non-U.S. Gov't"
      ],
      "correction_notices": [],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "full_text_complete",
      "complete_paper_examined_in_this_update": false
    },
    {
      "id": "P36876740",
      "pmid": "36876740",
      "doi": "10.1056/NEJMoa2215024",
      "title": "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36876740/",
      "issue_year": "2023",
      "electronic_date": "2023-03-04",
      "access_depth": "abstract_excerpt_checked",
      "checked_details": "Primary record and selected abstract passages checked; no complete-paper appraisal credited.",
      "publication_types": [
        "Randomized Controlled Trial",
        "Journal Article"
      ],
      "correction_notices": [],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "abstract_metadata",
      "complete_paper_examined_in_this_update": false
    },
    {
      "id": "P41211925",
      "pmid": "41211925",
      "doi": "10.1056/NEJMoa2514428",
      "title": "Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41211925/",
      "issue_year": "2026",
      "electronic_date": "2025-11-08",
      "access_depth": "abstract_excerpt_checked",
      "checked_details": "Primary record and selected abstract passages checked; no complete-paper appraisal credited.",
      "publication_types": [
        "Journal Article",
        "Randomized Controlled Trial",
        "Multicenter Study",
        "Clinical Trial, Phase III"
      ],
      "correction_notices": [],
      "cohort_note": "No independence claim made; cohort identity beyond the cited report was not exhaustively audited.",
      "baseline_access_depth": "abstract_metadata",
      "complete_paper_examined_in_this_update": false
    }
  ],
  "access_counts": {
    "full_text_partial": 1,
    "abstract_excerpt_checked": 8,
    "metadata_only": 0
  },
  "browser_messages": 2,
  "targeted_check": {
    "pmid": "32203549",
    "provider_access": "selected primary full-text passages reported by Consensus",
    "independent_primary_body_crosscheck": true,
    "verification_scope": "Methods table and instrument-strength paragraph: conditional apoB F-statistics of 36 and 66 are present in the primary text, although unavailable in Consensus excerpts. These do not imply every correlated exposure is independently identified."
  },
  "editorial_warning": "VESALIUS-CV has a 2026 issue date and a 2025 electronic publication date. Its high-risk first-event population is narrower than a claim about all primary prevention.",
  "reading_limit": "This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.",
  "method": "Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected."
}